Drug Profile
Research programme: antibody therapeutics - Adimab
Latest Information Update: 23 Jun 2023
Price :
$50
*
At a glance
- Originator Adimab
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer